Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02351037
Other study ID # PCYC-1131-CA
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date February 2015
Est. completion date April 2017

Study information

Verified date July 2018
Source Pharmacyclics LLC.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of ibrutinib alone or in combination with either cytarabine or azacitidine in the treatment of subjects with Acute Myeloid Leukemia (AML) who have failed standard treatment, or subjects without prior therapy who refuse standard chemotherapy.


Recruitment information / eligibility

Status Terminated
Enrollment 36
Est. completion date April 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female = 18 years of age.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Subjects with pathologically documented AML that has failed standard treatment, or subjects without prior therapy who refuse standard treatment options

- Bone marrow aspirate/biopsy results showing >5% blasts

- WBC count <25,000 cells/mm3 (25 x 109/L)

- Platelet count >10,000 cells/mm3 (10 x 109/L)

- Adequate hepatic and renal function defined as:

- For Cohorts 1 and 2: serum aspartate transaminase (AST) or alanine transaminase (ALT) =3.0 x upper limit of normal (ULN); for Cohort 3: ALT =2.5 or AST =2.5 ULN.

- Serum creatinine =2 mg/dL or Estimated Creatinine Clearance =30 mL/min (Cockcroft-Gault).

- Bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).

- PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN (When treated with warfarin or other vitamin K antagonists, then INR =3.0).

- Female subjects who are of non-reproductive potential (Female subjects of reproductive potential must have a negative serum pregnancy test upon study entry).

- Male and female subjects of reproductive potential agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug.

Exclusion Criteria:

- Acute promyelocytic leukemia (French-American-British Class M3 AML).

- Known active central nervous system (CNS) leukemia.

- Known active systemic infection (Grade =2).

- Active bleeding disorders or clinical signs of bleeding (Grade =2).

- Prior bone marrow transplant that requires immunosuppressant therapy or presents with graft vs host disease (GVHD).

- History of other malignancies, except:

- Malignancy treated with curative intent and with no known active disease present for =3 years before the first dose of study drug and with low risk of recurrence by treating physician.

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.

- Adequately treated carcinoma in situ without evidence of disease.

- Prior treatment with a BTK inhibitor.

- For Cohort 3 subjects, prior treatment with hypomethylating agents (eg, azacitidine, decitabine)

- Anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) prior to first dose of study drug.

- Subject has received a monoclonal antibody for anticancer intent within 8 weeks prior to the first dose of study drug.

- Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.

- Recent infection requiring intravenous (IV) systemic treatment that was completed =14 days before the first dose of study drug.

- Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), Grade 0 or 1, unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia.

- Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.

- History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

- Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.

- Major surgery within 4 weeks of first dose of study drug.

- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.

- Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.

- Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.

- Concomitant use of warfarin or other Vitamin K antagonists.

- Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor

- Currently active, clinically significant hepatic impairment (= moderate hepatic impairment according to the Child Pugh classification).

- Lactating or pregnant.

- Unwilling or unable to participate in all required study evaluations and procedures.

- Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Study Design


Intervention

Drug:
Ibrutinib
Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
Ibrutinib + LD-AraC
Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
Ibrutinib+Azacitidine
Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).

Locations

Country Name City State
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Montefiore Einstein Center for Cancer Research Bronx New York
United States Roswell Park Cancer Institute Buffalo New York
United States The University of Chicago Medical Center Chicago Illinois
United States City of Hope Duarte California
United States MD Anderson Cancer Center Houston Texas
United States University of Iowa Iowa City Iowa
United States UC Davis Medical Center Sacramento California
United States Fred Hutchinson Cancer Research Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Pharmacyclics LLC.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Using the Overall Remission Rate (Defined as Proportion of Subjects Achieving a CR or CRi) According to the LeukemiaNet Guidelines Dohner's 2000 Criteria for AML: Complete Response (CR), Bone marrow blasts < 5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count > 1.0 x 109/L (1000/µL); platelet count >100 x 109/L (100 000/µL); independence of red cell transfusions; CR with Incomplete Recovery (CRi), All CR criteria except for residual neutropenia (< 1.0 x 109/L [1000/µL]) or thrombocytopenia (<100 x 109/L [100 000/µL]) ; Morphologic leukemia-free state, Bone marrow blasts < 5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required; Partial Remission (PR), All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%; Relapse, Bone marrow blasts > 5%; or reappearance of blasts in the blood; or development of extramedullary disease. When the last subject enrolled completes approximately 12 months of treatment.
Primary Safety and Tolerability of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Number of Participants with Adverse Events and number of patients with lab abnormalities.The safety profile of ibrutinib was evaluated based on the incidence of adverse events (AEs) as well as clinically significant laboratory abnormalities and vital signs, and other malignancies. The safety evaluations performed in this study were standard and/or were required based on the safety data available from other clinical and preclinical settings. Up to 30 days following the last dose of study drug.
Secondary Relapse-free Survival (RFS), Event-free Survival (EFS) and Overall Survival (OS) To evaluate clinical efficacy by assessing relapse-free survival (RFS), event-free survival (EFS) and overall survival (OS). When the last subject enrolled completes approximately 12 months of treatment
Secondary Clinical Benefit Rate - as Defined as the Proportion of Subjects Who Achieve CR, CRi, Morphologic Leukemia-free State, or Partial Remission (PR) To evaluate clinical benefit defined as CR, CRi, morphologic leukemia-free state, and partial remission (PR). When the last subject enrolled completes approximately 12 months of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04240002 - A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Completed NCT02626715 - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS Phase 2
Completed NCT05488613 - Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Terminated NCT02927938 - Leukemia Stem Cell Detection in Acute Myeloid Leukemia Phase 3
Completed NCT01772953 - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT Phase 2
Recruiting NCT03188874 - Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Completed NCT00071006 - AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT04079296 - A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) Phase 1/Phase 2
Completed NCT04509622 - A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) Phase 3
Withdrawn NCT03699384 - Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Phase 1/Phase 2
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Completed NCT02252107 - 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 Phase 2
Terminated NCT01463410 - Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler N/A
Completed NCT01242774 - Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Phase 1
Terminated NCT02134782 - Yoga Fatigue Study N/A
Completed NCT01685619 - AML-MDS Novel Prognostic Tests Clinical Study
Completed NCT03625505 - A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04266795 - A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy Phase 2